Association Between Low-Dose Aspirin Use and Colorectal Cancer Incidence in Taiwan

Population-based East Asian data have corroborated reports from non-Asian settings on the association between low-dose aspirin and a lower risk of colorectal cancer (CRC). To evaluate the association between duration and recency of low-dose aspirin use and CRC risk. This nested case-control study in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA network open 2020-11, Vol.3 (11), p.e2026494-e2026494
Hauptverfasser: Lin, Hui-Min Diana, Vora, Pareen, Soriano-Gabarró, Montse, Chan, K Arnold
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e2026494
container_issue 11
container_start_page e2026494
container_title JAMA network open
container_volume 3
creator Lin, Hui-Min Diana
Vora, Pareen
Soriano-Gabarró, Montse
Chan, K Arnold
description Population-based East Asian data have corroborated reports from non-Asian settings on the association between low-dose aspirin and a lower risk of colorectal cancer (CRC). To evaluate the association between duration and recency of low-dose aspirin use and CRC risk. This nested case-control study included individuals who initiated aspirin use and matched individuals who did not use aspirin. Data were collected from Taiwan National Health Insurance and Taiwan Cancer Registry from 2000 through 2015. CRC cases were age- and sex-matched in a 1:4 ratio with individuals in a control group, identified from a cohort of individuals who used and did not use aspirin through risk-set sampling. Data analysis was conducted from June 2018 to July 2019. Low-dose aspirin use was defined as receiving less than 150 mg per day, whereas 100 mg/d was most commonly used. Based on duration and recency of low-dose aspirin use between cohort entry (initiation date of low-dose aspirin for aspirin use group or randomly assigned date for those who did not use aspirin) and index date (CRC diagnosis date for individuals in the case group and the diagnosis date for the 4 corresponding matched individuals in the control group), the 3 following mutually exclusive exposure groups served as the basis for analysis: (1) long-term current low-dose aspirin use, (2) episodic low-dose aspirin use, and (3) no low-dose aspirin use (the reference group). CRC risk among the 3 exposure groups. Among 4 710 504 individuals (2 747 830 [51.7%] men; median [interquartile range] age at cohort entry in initiator group, 61 [52-71] years; median [interquartile range] age at cohort entry in nonuse group, 59 [51-68] years), 79 095 CRC cases (1.7% of study cohort) were identified. Compared with no low-dose aspirin use, the adjusted odds ratio (OR) for long-term current low-dose aspirin use and CRC risk was 0.89 (95% CI, 0.85-0.93); for episodic use, 0.88 (95% CI, 0.86-0.89). Adjusted ORs of 0.69 (95% CI, 0.63-0.76) and 0.64 (95% CI, 0.61-0.67) were observed for long-term current use and episodic low-dose aspirin use within the subcohort of individuals who initiated low-dose aspirin between age 40 and 59 years. In this study, low-dose aspirin use was associated with 11% lower CRC risk in an East Asian population, and this association was larger when low-dose aspirin use started before age 60 years.
doi_str_mv 10.1001/jamanetworkopen.2020.26494
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7677757</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2667883985</sourcerecordid><originalsourceid>FETCH-LOGICAL-a473t-f03ff2ba63075a4b2c6f11b9e0e619d28b7b2f7479bff1febd34a9ccac6aea143</originalsourceid><addsrcrecordid>eNpdkU9PGzEQxa2KqiDKV6hWcOGyqf-tvcsBKU1pixSpUgVna9Y7bh02drA3jfrtcQpFlNM8aX7zNDOPkFNGZ4xS9nEFawg47WK6ixsMM045nXElO_mGHPFGy1q0tDl4oQ_JSc4rSgvIRKead-RQCM4Yo90R-THPOVoPk4-h-lR8EUO1jLv6c8xYzfPGJx-q26IhDNUijjGhnWCsFhAspuo6WD9gkVXBbsDvILwnbx2MGU-e6jG5_XJ1s_hWL79_vV7MlzVILabaUeEc70EJqhuQPbfKMdZ3SFGxbuBtr3vutNRd7xxz2A9CQmctWAUITIpjcvnou9n2axwshinBaDbJryH9MRG8-b8T_C_zM_42WmmtG10Mzp8MUrzfYp7M2meL41geHLfZcKm43L-JF_TsFbqK2xTKeYYrpdtWdG1TqItHyqaYc0L3vAyjZp-eeZWe2adn_qZXhj-8POd59F9W4gF4Ppxy</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2667883985</pqid></control><display><type>article</type><title>Association Between Low-Dose Aspirin Use and Colorectal Cancer Incidence in Taiwan</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Lin, Hui-Min Diana ; Vora, Pareen ; Soriano-Gabarró, Montse ; Chan, K Arnold</creator><creatorcontrib>Lin, Hui-Min Diana ; Vora, Pareen ; Soriano-Gabarró, Montse ; Chan, K Arnold</creatorcontrib><description>Population-based East Asian data have corroborated reports from non-Asian settings on the association between low-dose aspirin and a lower risk of colorectal cancer (CRC). To evaluate the association between duration and recency of low-dose aspirin use and CRC risk. This nested case-control study included individuals who initiated aspirin use and matched individuals who did not use aspirin. Data were collected from Taiwan National Health Insurance and Taiwan Cancer Registry from 2000 through 2015. CRC cases were age- and sex-matched in a 1:4 ratio with individuals in a control group, identified from a cohort of individuals who used and did not use aspirin through risk-set sampling. Data analysis was conducted from June 2018 to July 2019. Low-dose aspirin use was defined as receiving less than 150 mg per day, whereas 100 mg/d was most commonly used. Based on duration and recency of low-dose aspirin use between cohort entry (initiation date of low-dose aspirin for aspirin use group or randomly assigned date for those who did not use aspirin) and index date (CRC diagnosis date for individuals in the case group and the diagnosis date for the 4 corresponding matched individuals in the control group), the 3 following mutually exclusive exposure groups served as the basis for analysis: (1) long-term current low-dose aspirin use, (2) episodic low-dose aspirin use, and (3) no low-dose aspirin use (the reference group). CRC risk among the 3 exposure groups. Among 4 710 504 individuals (2 747 830 [51.7%] men; median [interquartile range] age at cohort entry in initiator group, 61 [52-71] years; median [interquartile range] age at cohort entry in nonuse group, 59 [51-68] years), 79 095 CRC cases (1.7% of study cohort) were identified. Compared with no low-dose aspirin use, the adjusted odds ratio (OR) for long-term current low-dose aspirin use and CRC risk was 0.89 (95% CI, 0.85-0.93); for episodic use, 0.88 (95% CI, 0.86-0.89). Adjusted ORs of 0.69 (95% CI, 0.63-0.76) and 0.64 (95% CI, 0.61-0.67) were observed for long-term current use and episodic low-dose aspirin use within the subcohort of individuals who initiated low-dose aspirin between age 40 and 59 years. In this study, low-dose aspirin use was associated with 11% lower CRC risk in an East Asian population, and this association was larger when low-dose aspirin use started before age 60 years.</description><identifier>ISSN: 2574-3805</identifier><identifier>EISSN: 2574-3805</identifier><identifier>DOI: 10.1001/jamanetworkopen.2020.26494</identifier><identifier>PMID: 33211109</identifier><language>eng</language><publisher>United States: American Medical Association</publisher><subject>Adult ; Age ; Age Factors ; Aged ; Aspirin ; Aspirin - therapeutic use ; Case-Control Studies ; Colorectal cancer ; Colorectal Neoplasms - epidemiology ; Colorectal Neoplasms - pathology ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Odds Ratio ; Online Only ; Original Investigation ; Pharmacy and Clinical Pharmacology ; Platelet Aggregation Inhibitors - therapeutic use ; Protective Factors ; Taiwan - epidemiology</subject><ispartof>JAMA network open, 2020-11, Vol.3 (11), p.e2026494-e2026494</ispartof><rights>2020. This work is published under https://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright 2020 Lin H-MD et al. .</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a473t-f03ff2ba63075a4b2c6f11b9e0e619d28b7b2f7479bff1febd34a9ccac6aea143</citedby><cites>FETCH-LOGICAL-a473t-f03ff2ba63075a4b2c6f11b9e0e619d28b7b2f7479bff1febd34a9ccac6aea143</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,864,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33211109$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lin, Hui-Min Diana</creatorcontrib><creatorcontrib>Vora, Pareen</creatorcontrib><creatorcontrib>Soriano-Gabarró, Montse</creatorcontrib><creatorcontrib>Chan, K Arnold</creatorcontrib><title>Association Between Low-Dose Aspirin Use and Colorectal Cancer Incidence in Taiwan</title><title>JAMA network open</title><addtitle>JAMA Netw Open</addtitle><description>Population-based East Asian data have corroborated reports from non-Asian settings on the association between low-dose aspirin and a lower risk of colorectal cancer (CRC). To evaluate the association between duration and recency of low-dose aspirin use and CRC risk. This nested case-control study included individuals who initiated aspirin use and matched individuals who did not use aspirin. Data were collected from Taiwan National Health Insurance and Taiwan Cancer Registry from 2000 through 2015. CRC cases were age- and sex-matched in a 1:4 ratio with individuals in a control group, identified from a cohort of individuals who used and did not use aspirin through risk-set sampling. Data analysis was conducted from June 2018 to July 2019. Low-dose aspirin use was defined as receiving less than 150 mg per day, whereas 100 mg/d was most commonly used. Based on duration and recency of low-dose aspirin use between cohort entry (initiation date of low-dose aspirin for aspirin use group or randomly assigned date for those who did not use aspirin) and index date (CRC diagnosis date for individuals in the case group and the diagnosis date for the 4 corresponding matched individuals in the control group), the 3 following mutually exclusive exposure groups served as the basis for analysis: (1) long-term current low-dose aspirin use, (2) episodic low-dose aspirin use, and (3) no low-dose aspirin use (the reference group). CRC risk among the 3 exposure groups. Among 4 710 504 individuals (2 747 830 [51.7%] men; median [interquartile range] age at cohort entry in initiator group, 61 [52-71] years; median [interquartile range] age at cohort entry in nonuse group, 59 [51-68] years), 79 095 CRC cases (1.7% of study cohort) were identified. Compared with no low-dose aspirin use, the adjusted odds ratio (OR) for long-term current low-dose aspirin use and CRC risk was 0.89 (95% CI, 0.85-0.93); for episodic use, 0.88 (95% CI, 0.86-0.89). Adjusted ORs of 0.69 (95% CI, 0.63-0.76) and 0.64 (95% CI, 0.61-0.67) were observed for long-term current use and episodic low-dose aspirin use within the subcohort of individuals who initiated low-dose aspirin between age 40 and 59 years. In this study, low-dose aspirin use was associated with 11% lower CRC risk in an East Asian population, and this association was larger when low-dose aspirin use started before age 60 years.</description><subject>Adult</subject><subject>Age</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Aspirin</subject><subject>Aspirin - therapeutic use</subject><subject>Case-Control Studies</subject><subject>Colorectal cancer</subject><subject>Colorectal Neoplasms - epidemiology</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Odds Ratio</subject><subject>Online Only</subject><subject>Original Investigation</subject><subject>Pharmacy and Clinical Pharmacology</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Protective Factors</subject><subject>Taiwan - epidemiology</subject><issn>2574-3805</issn><issn>2574-3805</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkU9PGzEQxa2KqiDKV6hWcOGyqf-tvcsBKU1pixSpUgVna9Y7bh02drA3jfrtcQpFlNM8aX7zNDOPkFNGZ4xS9nEFawg47WK6ixsMM045nXElO_mGHPFGy1q0tDl4oQ_JSc4rSgvIRKead-RQCM4Yo90R-THPOVoPk4-h-lR8EUO1jLv6c8xYzfPGJx-q26IhDNUijjGhnWCsFhAspuo6WD9gkVXBbsDvILwnbx2MGU-e6jG5_XJ1s_hWL79_vV7MlzVILabaUeEc70EJqhuQPbfKMdZ3SFGxbuBtr3vutNRd7xxz2A9CQmctWAUITIpjcvnou9n2axwshinBaDbJryH9MRG8-b8T_C_zM_42WmmtG10Mzp8MUrzfYp7M2meL41geHLfZcKm43L-JF_TsFbqK2xTKeYYrpdtWdG1TqItHyqaYc0L3vAyjZp-eeZWe2adn_qZXhj-8POd59F9W4gF4Ppxy</recordid><startdate>20201102</startdate><enddate>20201102</enddate><creator>Lin, Hui-Min Diana</creator><creator>Vora, Pareen</creator><creator>Soriano-Gabarró, Montse</creator><creator>Chan, K Arnold</creator><general>American Medical Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20201102</creationdate><title>Association Between Low-Dose Aspirin Use and Colorectal Cancer Incidence in Taiwan</title><author>Lin, Hui-Min Diana ; Vora, Pareen ; Soriano-Gabarró, Montse ; Chan, K Arnold</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a473t-f03ff2ba63075a4b2c6f11b9e0e619d28b7b2f7479bff1febd34a9ccac6aea143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Age</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Aspirin</topic><topic>Aspirin - therapeutic use</topic><topic>Case-Control Studies</topic><topic>Colorectal cancer</topic><topic>Colorectal Neoplasms - epidemiology</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Odds Ratio</topic><topic>Online Only</topic><topic>Original Investigation</topic><topic>Pharmacy and Clinical Pharmacology</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Protective Factors</topic><topic>Taiwan - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lin, Hui-Min Diana</creatorcontrib><creatorcontrib>Vora, Pareen</creatorcontrib><creatorcontrib>Soriano-Gabarró, Montse</creatorcontrib><creatorcontrib>Chan, K Arnold</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>JAMA network open</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lin, Hui-Min Diana</au><au>Vora, Pareen</au><au>Soriano-Gabarró, Montse</au><au>Chan, K Arnold</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association Between Low-Dose Aspirin Use and Colorectal Cancer Incidence in Taiwan</atitle><jtitle>JAMA network open</jtitle><addtitle>JAMA Netw Open</addtitle><date>2020-11-02</date><risdate>2020</risdate><volume>3</volume><issue>11</issue><spage>e2026494</spage><epage>e2026494</epage><pages>e2026494-e2026494</pages><issn>2574-3805</issn><eissn>2574-3805</eissn><abstract>Population-based East Asian data have corroborated reports from non-Asian settings on the association between low-dose aspirin and a lower risk of colorectal cancer (CRC). To evaluate the association between duration and recency of low-dose aspirin use and CRC risk. This nested case-control study included individuals who initiated aspirin use and matched individuals who did not use aspirin. Data were collected from Taiwan National Health Insurance and Taiwan Cancer Registry from 2000 through 2015. CRC cases were age- and sex-matched in a 1:4 ratio with individuals in a control group, identified from a cohort of individuals who used and did not use aspirin through risk-set sampling. Data analysis was conducted from June 2018 to July 2019. Low-dose aspirin use was defined as receiving less than 150 mg per day, whereas 100 mg/d was most commonly used. Based on duration and recency of low-dose aspirin use between cohort entry (initiation date of low-dose aspirin for aspirin use group or randomly assigned date for those who did not use aspirin) and index date (CRC diagnosis date for individuals in the case group and the diagnosis date for the 4 corresponding matched individuals in the control group), the 3 following mutually exclusive exposure groups served as the basis for analysis: (1) long-term current low-dose aspirin use, (2) episodic low-dose aspirin use, and (3) no low-dose aspirin use (the reference group). CRC risk among the 3 exposure groups. Among 4 710 504 individuals (2 747 830 [51.7%] men; median [interquartile range] age at cohort entry in initiator group, 61 [52-71] years; median [interquartile range] age at cohort entry in nonuse group, 59 [51-68] years), 79 095 CRC cases (1.7% of study cohort) were identified. Compared with no low-dose aspirin use, the adjusted odds ratio (OR) for long-term current low-dose aspirin use and CRC risk was 0.89 (95% CI, 0.85-0.93); for episodic use, 0.88 (95% CI, 0.86-0.89). Adjusted ORs of 0.69 (95% CI, 0.63-0.76) and 0.64 (95% CI, 0.61-0.67) were observed for long-term current use and episodic low-dose aspirin use within the subcohort of individuals who initiated low-dose aspirin between age 40 and 59 years. In this study, low-dose aspirin use was associated with 11% lower CRC risk in an East Asian population, and this association was larger when low-dose aspirin use started before age 60 years.</abstract><cop>United States</cop><pub>American Medical Association</pub><pmid>33211109</pmid><doi>10.1001/jamanetworkopen.2020.26494</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2574-3805
ispartof JAMA network open, 2020-11, Vol.3 (11), p.e2026494-e2026494
issn 2574-3805
2574-3805
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7677757
source MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Adult
Age
Age Factors
Aged
Aspirin
Aspirin - therapeutic use
Case-Control Studies
Colorectal cancer
Colorectal Neoplasms - epidemiology
Colorectal Neoplasms - pathology
Female
Humans
Male
Middle Aged
Neoplasm Staging
Odds Ratio
Online Only
Original Investigation
Pharmacy and Clinical Pharmacology
Platelet Aggregation Inhibitors - therapeutic use
Protective Factors
Taiwan - epidemiology
title Association Between Low-Dose Aspirin Use and Colorectal Cancer Incidence in Taiwan
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T05%3A59%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20Between%20Low-Dose%20Aspirin%20Use%20and%20Colorectal%20Cancer%20Incidence%20in%20Taiwan&rft.jtitle=JAMA%20network%20open&rft.au=Lin,%20Hui-Min%20Diana&rft.date=2020-11-02&rft.volume=3&rft.issue=11&rft.spage=e2026494&rft.epage=e2026494&rft.pages=e2026494-e2026494&rft.issn=2574-3805&rft.eissn=2574-3805&rft_id=info:doi/10.1001/jamanetworkopen.2020.26494&rft_dat=%3Cproquest_pubme%3E2667883985%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2667883985&rft_id=info:pmid/33211109&rfr_iscdi=true